Sanofi will acquire the exclusive rights of Jixing Pharmaceutical to develop and commercialize Aficamten in Greater China
白云追月素
发表于 2024-12-20 14:17:28
146
0
0
Securities Times E-Company News: Sanofi and Jixing Pharmaceutical announced today the signing of a formal agreement, which stipulates that Sanofi will acquire Jixing Pharmaceutical's exclusive rights to develop and commercialize Aficamten in Greater China. The transaction is expected to be completed within 2024, and the transaction amount is not publicly disclosed.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Qualcomm's interest in acquiring Intel reportedly cooled down or considering equity deal
- Porsche's acquisition of Valta equity has been unconditionally approved by the State Administration for Market Regulation
- Alibaba plans to sell 100% equity of Intime to Yagor Group and others for 7.4 billion yuan, with an expected loss of approximately 9.3 billion yuan
- Alibaba sells equity in Intime for 7.4 billion yuan
- Alibaba loses 9.3 billion yuan, sells 100% equity of Intime, Youngor invests in another city
- Sanofi and Jixing reach agreement on Aficamten in Greater China market
- Sanofi and Jixing announce agreement on Aficamten in Greater China market
- Beike: Terminate the acquisition of all remaining equity of Space Intelligence, a home decoration service provider
- Beike: Terminate the acquisition of all remaining equity in Space Intelligence
- Beike terminates acquisition of all remaining equity of Love Space's parent company
